Business● Low1h ago · Nov 4, 2026, 12:17 AM
Alkermes reiterates $400M-$420M Q4 proprietary net sales outlook while targeting mid-2027 alixorexton Phase III data
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Alkermes has reiterated its Q4 proprietary net sales outlook between $400M-$420M. The company is also targeting mid-2027 for Phase III data related to alixorexton.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business33m agoGlobal Industrial anticipates Q4 gross margin in line with last year’s 34.5% amid transportation cost headwindsSeeking Alpha TechBusiness42m agoCorcept targets $3B-$5B in Cushing’s revenue in 2030 as it awaits December 17 relacorilant FDA decisionSeeking Alpha TechBusiness43m agoCelanese targets $700M-$800M 2027 free cash flow as cost and interest savings buildSeeking Alpha TechBusiness43m agoKodak signals AMC as “growth engine” while focusing on cash generationSeeking Alpha Tech